Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countries.
Zoltán KalóMaciej NiewadaTamás BereczkyWim GoettschRick A VremanEntela XoxiMark TrusheimMarcelien H E CallenbachLászló NagySteven SimoensPublished in: Expert review of pharmacoeconomics & outcomes research (2023)
Whilst pricing and reimbursement decisions will remain a competence of EU member states, there is a need for alignment of European pharmaceutical payment model components in critical areas with the ultimate objective of improving the equitable access of European patients to increasingly complex pharmaceutical technologies.